Pharmaceuticals, Biotechnology and Life Sciences
Advisors will support the company’s ongoing expansion of its technology for cell and gene therapy applications SAN FRANCISCO–(BUSINESS WIRE)–Xcell Biosciences…
Dr. Kerstein brings significant experience in the development of small molecule oncology therapeutics including in gastrointestinal stromal tumors (GIST) as…
— Completed Enrollment of 190 Patients for Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial; Pivotal CR Data Expected by…
Certification demonstrates Rip Road’s adherence to regulatory standards and commitment to safety, data security, and effective engineering processes. The Rip…
The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive…
Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA Agreement by FDA…
– Engaged CRO for first-in-human SAT-3247 Phase 1 clinical study – Initiated GLP toxicity studies and GMP manufacturing of SAT-3247…
Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) to be reported in…
– Initiated final IND/CTA enabling studies for lead in vivo gene editing program PBGENE-HBV; expect to submit IND and/or CTA…
ESPOO, Finland & NOIDA, India–(BUSINESS WIRE)–#ERP—HCLTech, a global technology company, announced that it has been selected by Oriola Corporation, a…